Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

RAPid SimPLE målrettet strålebehandling for hjernemetastaser (RAPPLE)

16. september 2026 opdateret af: British Columbia Cancer Agency

Randomiseret fase II non-inferioritetsundersøgelse af 5-dages versus 1-dages RAPid SimPLE (RAPPLE) målrettet strålebehandling for hjernemetastaser

The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Detaljeret beskrivelse

Hypothesis For selected patients with limited life expectancy, a single targeted fraction of 8 Gy / 1 to brain metastases will provide equivalent survival as targeted radiotherapy with 20 Gy / 5 to brain metastases.

Justification The QUARTZ study randomized patients with brain metastases and poor prognosis between 20 Gy / 5 whole brain radiotherapy (WBRT) and best supportive care. The median survival in both arms of the study was 9 weeks. The quality of life in both arm was also the same. It is known that WBRT significantly diminishes quality of life. The investigators interpretation of the QUARTZ trial is that the unchecked growth of brain metastases in the best supportive care arm diminishes quality of life as much as WBRT. To control brain metastases without giving WBRT, targeted treatment with 20 Gy / 5 to the metastases alone is standard care at BC Cancer. Numerous randomized trials have compared the efficacy of 20-30 Gy / 5-10 fractions and 8 Gy / 1 for palliative treatment of pain from bone metastases. In addition, there is a randomized trial showing that 20 Gy / 5 and 8 Gy /1 are equally effective for the treatment of symptoms from spinal cord compression. This study will test the use of this shorter, one-visit treatment schedule against the standard 5-visit treatment schedule for patients with brain metastases.

Research Design Randomized Phase II Non-Inferiority Study. The estimated median survival for this cohort, based upon a prior cohort study from 2012-2016 at BC Cancer is 3 months (13 weeks). The investigators would regard a study median survival of less than the 9-week median survival observed in the QUARTZ trial as unacceptable. Hence, the hazard ratio for the experimental arm and the control arm is: 13 weeks / 9 weeks = 1.44. With one-sided Type I error set at alpha = 0.2 and power = 0.8, the investigators calculated a theoretical sample size of 86 patients. Based on prior experience with clinical trials for patients with brain metastases, a 15% risk of drop-out and loss to follow up is expected. Hence the final sample size will be 100 patients. Stratification by the diagnosis-specific graded prognostic assessment (DS-GPA) ranges of 0.0 - 1.0 and 1.5 - 2.0 and lung cancer versus other histologies will help to ensure baseline characteristics that predict for equal survival are equally distributed in both arms of the study.

Statistical Analysis The primary endpoint is overall survival. The study will be considered to be a positive phase II non-inferiority study if the median survival in the experimental arm is within 4 weeks of the median survival in the standard arm.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • British Columbia
      • Abbotsford British Columbia, British Columbia, Canada
        • BC Cancer - Abbotsford
      • Kelowna, British Columbia, Canada, V1Y5L3
        • BC Cancer - Kelowna
      • Prince George, British Columbia, Canada, V2M7E9
        • BC Cancer - Prince George
      • Surrey, British Columbia, Canada
        • BC Cancer - Surrey
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • BC Cancer - Vancouver
      • Victoria, British Columbia, Canada
        • BC Cancer - Victoria

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 100 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Patients must fulfil all the following criteria to be eligible for admission to the study:

  • Age ≥ 18
  • Pathological diagnosis of a non-hematopoietic malignancy
  • Brain metastases of any size
  • Any number of untreated or progressing, previously treated brain metastases that can all be contoured and targeted
  • Presence of extracranial disease
  • Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) ≤ 2.0 (https://brainmetgpa.com/) or Graded Prognostic Assessment ≤ 2.0 (Appendix I)
  • Able to complete the EuroQOL (EQ-5D-5L) questionnaire
  • Willing and able to have regular imaging follow up
  • Feasible to start protocol treatment within 14 calendar days of participant enrolment
  • Karnofsky Performance Score (KPS) ≥ 50

Exclusion Criteria

Patients who fulfill any of the following criteria are not eligible for admission to the study:

  • Inability to have a brain MRI.
  • WBRT less than 3 months prior to randomization
  • Disseminated leptomeningeal carcinomatosis (limited pachymeningeal disease is permitted)
  • Multiple sclerosis
  • Neurologically declining despite corticosteroids
  • Appropriate for surgery or stereotactic radiosurgery
  • Germ cell and primary brain tumours
  • Systemic lupus erythematosis, scleroderma, or other connective tissue disorders not in remission
  • Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the patient's safety, preclude safe administration of the planned protocol treatment, or prevent the patient from being managed according to the protocol guidelines
  • Pregnancy
  • Potentially fertile men or women of childbearing potential who are unwilling to employ highly effective contraception

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: 20 Gy in 5 Fractions Volumetric Modulated Arc Therapy to Brain Metastases

Five treatments of 4 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.

Volumetric Modulated Arc Therapy

Eksperimentel: 8 Gy in 1 Fraction Volumetric Modulated Arc Therapy to Brain Metastases

A single treatment of 8 Gy will be delivered using volumetric modulated arc therapy on a conventional linear accelerator in a conventional head shell without the use of stereotactic radiosurgery technique.

Volumetric Modulated Arc Therapy

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Survival Time
Tidsramme: 1 year

The median time from randomization to death

1 year

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Median Time to Decline in Karnofsky Performance Status
Tidsramme: 1 year

The time from randomization to a 20-point decline in Karnofsky Performance Status

1 year
Control of treated brain metastases
Tidsramme: 1 year

Cumulative incidence of local recurrence of treated metastases

1 year
Corticosteroid use
Tidsramme: 6 weeks

Proportion of patients taking corticosteroids

6 weeks
Control of brain disease
Tidsramme: 1 year

Cumulative incidence of (local recurrence of treated metastases OR new metastases)

1 year
Retreatments for brain metastases
Tidsramme: 1 year

Proportion of patients with retreatment for brain metastases after radiotherapy

1 year
Adverse Events
Tidsramme: 1 year

Cumulative incidence of adverse events, graded using CTCAE Version 5.0

1 year
Health-Related Quality of Life
Tidsramme: 1 year

Median time to a minimum clinically important decline in Health-Related Quality of Life

1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Alan Nichol, MD, BC Cancer Vancouver

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juli 2022

Primær færdiggørelse (Anslået)

30. december 2026

Studieafslutning (Anslået)

30. december 2027

Datoer for studieregistrering

Først indsendt

4. august 2021

Først indsendt, der opfyldte QC-kriterier

17. september 2021

Først opslået (Faktiske)

21. september 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner